MNMD
Price
$9.91
Change
-$0.04 (-0.40%)
Updated
Sep 24, 12:16 PM (EDT)
Capitalization
757.08M
49 days until earnings call
ZLDPF
Price
$70.90
Change
-$1.17 (-1.62%)
Updated
Sep 22 closing price
Capitalization
4.94B
Interact to see
Advertisement

MNMD vs ZLDPF

Header iconMNMD vs ZLDPF Comparison
Open Charts MNMD vs ZLDPFBanner chart's image
Mind Medicine (MindMed)
Price$9.91
Change-$0.04 (-0.40%)
Volume$1.86K
Capitalization757.08M
Zealand Pharma A/S
Price$70.90
Change-$1.17 (-1.62%)
Volume$225
Capitalization4.94B
MNMD vs ZLDPF Comparison Chart in %
Loading...
MNMD
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
ZLDPF
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
MNMD vs. ZLDPF commentary
Sep 24, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is MNMD is a Buy and ZLDPF is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Sep 24, 2025
Stock price -- (MNMD: $9.95 vs. ZLDPF: $70.90)
Brand notoriety: MNMD and ZLDPF are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: MNMD: 207% vs. ZLDPF: 40%
Market capitalization -- MNMD: $757.08M vs. ZLDPF: $4.94B
MNMD [@Biotechnology] is valued at $757.08M. ZLDPF’s [@Biotechnology] market capitalization is $4.94B. The market cap for tickers in the [@Biotechnology] industry ranges from $97.36B to $0. The average market capitalization across the [@Biotechnology] industry is $1.91B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

MNMD’s FA Score shows that 0 FA rating(s) are green whileZLDPF’s FA Score has 2 green FA rating(s).

  • MNMD’s FA Score: 0 green, 5 red.
  • ZLDPF’s FA Score: 2 green, 3 red.
According to our system of comparison, ZLDPF is a better buy in the long-term than MNMD.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

MNMD’s TA Score shows that 6 TA indicator(s) are bullish while ZLDPF’s TA Score has 4 bullish TA indicator(s).

  • MNMD’s TA Score: 6 bullish, 2 bearish.
  • ZLDPF’s TA Score: 4 bullish, 5 bearish.
According to our system of comparison, MNMD is a better buy in the short-term than ZLDPF.

Price Growth

MNMD (@Biotechnology) experienced а +2.47% price change this week, while ZLDPF (@Biotechnology) price change was +3.40% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +4.35%. For the same industry, the average monthly price growth was +10.13%, and the average quarterly price growth was +53.94%.

Reported Earning Dates

MNMD is expected to report earnings on Nov 12, 2025.

Industries' Descriptions

@Biotechnology (+4.35% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
ZLDPF($4.94B) has a higher market cap than MNMD($757M). MNMD YTD gains are higher at: 42.960 vs. ZLDPF (-30.735). ZLDPF has higher annual earnings (EBITDA): 7.27B vs. MNMD (-110.19M). ZLDPF has more cash in the bank: 16.6B vs. MNMD (183M). MNMD has less debt than ZLDPF: MNMD (41.2M) vs ZLDPF (397M). ZLDPF has higher revenues than MNMD: ZLDPF (9.11B) vs MNMD (0).
MNMDZLDPFMNMD / ZLDPF
Capitalization757M4.94B15%
EBITDA-110.19M7.27B-2%
Gain YTD42.960-30.735-140%
P/E RatioN/A4.86-
Revenue09.11B-
Total Cash183M16.6B1%
Total Debt41.2M397M10%
FUNDAMENTALS RATINGS
MNMD vs ZLDPF: Fundamental Ratings
MNMD
ZLDPF
OUTLOOK RATING
1..100
6891
VALUATION
overvalued / fair valued / undervalued
1..100
38
Fair valued
34
Fair valued
PROFIT vs RISK RATING
1..100
9272
SMR RATING
1..100
9819
PRICE GROWTH RATING
1..100
4252
P/E GROWTH RATING
1..100
10023
SEASONALITY SCORE
1..100
36n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

ZLDPF's Valuation (34) in the null industry is in the same range as MNMD (38). This means that ZLDPF’s stock grew similarly to MNMD’s over the last 12 months.

ZLDPF's Profit vs Risk Rating (72) in the null industry is in the same range as MNMD (92). This means that ZLDPF’s stock grew similarly to MNMD’s over the last 12 months.

ZLDPF's SMR Rating (19) in the null industry is significantly better than the same rating for MNMD (98). This means that ZLDPF’s stock grew significantly faster than MNMD’s over the last 12 months.

MNMD's Price Growth Rating (42) in the null industry is in the same range as ZLDPF (52). This means that MNMD’s stock grew similarly to ZLDPF’s over the last 12 months.

ZLDPF's P/E Growth Rating (23) in the null industry is significantly better than the same rating for MNMD (100). This means that ZLDPF’s stock grew significantly faster than MNMD’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
MNMDZLDPF
RSI
ODDS (%)
N/A
Bearish Trend 2 days ago
48%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
86%
Bearish Trend 2 days ago
52%
Momentum
ODDS (%)
Bullish Trend 2 days ago
84%
Bearish Trend 2 days ago
62%
MACD
ODDS (%)
Bullish Trend 2 days ago
83%
Bearish Trend 2 days ago
45%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
86%
Bullish Trend 2 days ago
56%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
85%
Bullish Trend 2 days ago
59%
Advances
ODDS (%)
Bullish Trend 2 days ago
84%
Bullish Trend 7 days ago
73%
Declines
ODDS (%)
Bearish Trend 6 days ago
86%
Bearish Trend 3 days ago
57%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
90%
N/A
Aroon
ODDS (%)
Bullish Trend 2 days ago
89%
Bullish Trend 2 days ago
68%
View a ticker or compare two or three
Interact to see
Advertisement
MNMD
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
ZLDPF
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
WQAIX12.340.02
+0.16%
Westwood Quality AllCap Institutional
JAAGX82.03-0.36
-0.44%
Janus Henderson VIT Enterprise Instl
PURYX60.90-0.36
-0.59%
Putnam Research Y
BGSIX83.96-0.97
-1.14%
BlackRock Technology Opportunities Instl
GSTSX11.60-0.14
-1.19%
Goldman Sachs Strategic Growth Svc

MNMD and

Correlation & Price change

A.I.dvisor indicates that over the last year, MNMD has been loosely correlated with OCUL. These tickers have moved in lockstep 51% of the time. This A.I.-generated data suggests there is some statistical probability that if MNMD jumps, then OCUL could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To MNMD
1D Price
Change %
MNMD100%
+4.30%
OCUL - MNMD
51%
Loosely correlated
+0.41%
ATAI - MNMD
50%
Loosely correlated
+14.96%
RXRX - MNMD
50%
Loosely correlated
-3.41%
EYPT - MNMD
49%
Loosely correlated
+0.22%
SYRE - MNMD
48%
Loosely correlated
+4.77%
More

ZLDPF and

Correlation & Price change

A.I.dvisor indicates that over the last year, ZLDPF has been loosely correlated with IMRN. These tickers have moved in lockstep 52% of the time. This A.I.-generated data suggests there is some statistical probability that if ZLDPF jumps, then IMRN could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ZLDPF
1D Price
Change %
ZLDPF100%
N/A
IMRN - ZLDPF
52%
Loosely correlated
-2.58%
MNMD - ZLDPF
32%
Poorly correlated
+4.30%
VICP - ZLDPF
28%
Poorly correlated
N/A
GLSI - ZLDPF
26%
Poorly correlated
-6.95%
LTRN - ZLDPF
23%
Poorly correlated
-2.16%
More